Nirvana enters supply agreement with Symeres
by CM Staff
Under this agreement, Symeres will supply Psilocybin and other materials for use in trials and ongoing research.
VANCOUVER — Nirvana Life Sciences Inc. has entered a supply agreement with Symeres B.V. for the supply of compounds to support the company’s ongoing research program.
Under this agreement, Symeres will supply Psilocybin and other materials for use in trials and ongoing research.
“We are very pleased to be able to work with a firm with the broad capabilities that Symeres offers as we enter the next phase of research and development,” said Dr. Sazzad Hossain, CEO of Nirvana in a statement.
“Symeres is one of Europe’s leading Contract Research Organizations that has the capacity to produce and supply many of the compounds essential to our research”.
